Merck CEO Belén Garijo Forecasts Organic Growth Recovery in 2024 Amid Solid First Quarter Performance

Financial results of Q1 2024 Healthcare with strong performance Electronics increases sales and earnings organically, driven by higher demand for semic...

May 15, 2024 | Wednesday | Company results
Charles River's CEO, James C. Foster, Optimistic About Growth Amidst First-Quarter Performance

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 bil...

May 13, 2024 | Monday | Company results
Bio-Rad's CEO, Norman Schwartz, Finds Hope in Adversity: "Our Vision Remains Strong Despite Market Challenges"

  First-quarter 2024 total net sales were $610.8 million, a decrease of 9.8 percent compared to $676.8 million reported for the first quarter of 2023...

May 08, 2024 | Wednesday | Company results
Twist Bioscience Sees Strong Growth, Revenue Reaches $75.3M in Q2FY24," Says CEO Emily M. Leproust

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today ...

May 03, 2024 | Friday | News
Emma Walmsley, CEO of GSK, Highlights Strong Start to 2024 with Impressive Performance and Pipeline Progress

Broad-based performance drives sales, profits and earnings growth: Total Q1 2024 sales £7.4 billion +10% and +13% ex COVID Vaccines sales +16...

May 02, 2024 | Thursday | Company results
QIAGEN's Quantum Leap: CEO Thierry Bernard Heralds First Quarter Triumph with Stellar Growth in Key Areas!

Q1 2024: Net sales of $459 million (-5% actual rates, -5% constant exchange rates, CER); diluted EPS of $0.36 and adjusted diluted EPS of $0.46 Net ...

April 30, 2024 | Tuesday | Company results
Gilead's CEO Daniel O'Day Projects Robust Growth in 2024 Amidst Promising Acquisition and Pipeline Advancements

Gilead Sciences Announces First Quarter 2024 Financial Results Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billion Biktarvy...

April 26, 2024 | Friday | Company results
Thermo Fisher Scientific - Marc N. Casper, Chairman and CEO, Attributes Q1 2024 Success to Proven Growth Strategy and Operational Excellence

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science,  reported its financial results for the first quarter ended March 30, ...

April 24, 2024 | Wednesday | Company results
Novartis Triumphs in Q1 2024: CEO Vas Narasimhan Announces Stellar Growth and Upgraded Forecasts

Under Narasimhan's leadership, the company sees significant sales and profit growth across major products, prompting an upward revision of the full-year 20...

April 23, 2024 | Tuesday | Company results
Merck's CEO Belén Garijo Champions Resilience and Growth Amidst 2023's Market Challenges, Sets Strategic Path for Sustainable Success

Financial results of fiscal 2023 Net sales decrease organically by 1.6% to € 21.0 billion EBITDA pre down organically by 9.0% to € ...

March 07, 2024 | Thursday | News
ICON CEO, Dr. Steve Cutler, Highlights Strong Performance and Affirms 2024 Financial Guidance

ICON plc (NASDAQ:ICLR), a global leader in healthcare intelligence and clinical research,  announced its financial results for the fourth quarter and ...

February 22, 2024 | Thursday | Company results
Bio-Rad's CEO, Norman Schwartz, Anticipates Sector Rebound in 2024 Amid Fourth Quarter Challenges

Bio-Rad Laboratories Inc. reports a 6.7% decrease in fourth-quarter net sales compared to 2022, largely attributed to ongoing weakness in biopharma markets...

February 16, 2024 | Friday | Company results
CEO Ari Bousbib Commends IQVIA's Resilience Amidst Challenging 2023 Landscape

  -IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a global leader in advanced analytics, technology solutions, and clinical research services ...

February 15, 2024 | Thursday | Company results
Catalent CEO Alessandro Maselli Celebrates Q2 Triumphs, Forges Transformative Alliance with Novo Holdings to Supercharge Growth

Q2'24 net revenue of $1.03 billion decreased 10% as reported, or 11% in constant currency(1), compared to Q2'23. Q2'24 net revenue, excluding COVID...

February 12, 2024 | Monday | Company results

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in